![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLCL1 |
Gene summary for PLCL1 |
![]() |
Gene information | Species | Human | Gene symbol | PLCL1 | Gene ID | 5334 |
Gene name | phospholipase C like 1 (inactive) | |
Gene Alias | PLCE | |
Cytomap | 2q33.1 | |
Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | Q15111 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5334 | PLCL1 | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 1.65e-02 | 7.60e-01 | -0.1406 |
5334 | PLCL1 | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 2.72e-02 | 6.42e-01 | -0.1408 |
5334 | PLCL1 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 1.10e-02 | 7.68e-01 | -0.138 |
5334 | PLCL1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 3.18e-22 | 9.05e-01 | -0.2116 |
5334 | PLCL1 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 4.08e-03 | 5.66e-01 | -0.1941 |
5334 | PLCL1 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 1.67e-07 | 7.41e-01 | -0.2107 |
5334 | PLCL1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.19e-08 | 5.81e-01 | -0.2119 |
5334 | PLCL1 | RNA-P6T1-P6T1-1 | Human | Lung | MIAC | 2.13e-04 | 9.36e-01 | -0.0238 |
5334 | PLCL1 | RNA-P6T1-P6T1-2 | Human | Lung | MIAC | 1.48e-05 | 1.06e+00 | -0.0186 |
5334 | PLCL1 | RNA-P6T1-P6T1-3 | Human | Lung | MIAC | 3.67e-02 | 7.89e-01 | -0.0296 |
5334 | PLCL1 | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 2.37e-08 | 1.06e+00 | -0.0263 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001810512 | Lung | AIS | peptidyl-serine phosphorylation | 60/1849 | 315/18723 | 4.75e-07 | 3.64e-05 | 60 |
GO:001820912 | Lung | AIS | peptidyl-serine modification | 61/1849 | 338/18723 | 2.49e-06 | 1.41e-04 | 61 |
GO:005109813 | Lung | AIS | regulation of binding | 61/1849 | 363/18723 | 2.48e-05 | 8.06e-04 | 61 |
GO:003209212 | Lung | AIS | positive regulation of protein binding | 19/1849 | 85/18723 | 5.23e-04 | 8.42e-03 | 19 |
GO:004339313 | Lung | AIS | regulation of protein binding | 34/1849 | 196/18723 | 8.16e-04 | 1.14e-02 | 34 |
GO:005109913 | Lung | AIS | positive regulation of binding | 30/1849 | 173/18723 | 1.61e-03 | 1.87e-02 | 30 |
GO:003209222 | Lung | AAH | positive regulation of protein binding | 9/613 | 85/18723 | 1.83e-03 | 4.29e-02 | 9 |
GO:001810521 | Lung | MIAC | peptidyl-serine phosphorylation | 37/967 | 315/18723 | 2.73e-06 | 3.12e-04 | 37 |
GO:001820921 | Lung | MIAC | peptidyl-serine modification | 37/967 | 338/18723 | 1.38e-05 | 9.86e-04 | 37 |
GO:00331351 | Lung | MIAC | regulation of peptidyl-serine phosphorylation | 16/967 | 144/18723 | 3.16e-03 | 4.23e-02 | 16 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLCL1 | SNV | Missense_Mutation | c.1465N>T | p.Leu489Phe | p.L489F | Q15111 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-38-4625-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PLCL1 | SNV | Missense_Mutation | novel | c.1622N>T | p.Gly541Val | p.G541V | Q15111 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-44-2662-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Other, specify in notesGSK Mage Vaccine Study | rec | PD |
PLCL1 | SNV | Missense_Mutation | c.1972N>C | p.Asp658His | p.D658H | Q15111 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-44-4112-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
PLCL1 | SNV | Missense_Mutation | c.2398N>T | p.Asp800Tyr | p.D800Y | Q15111 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-49-AAR2-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | taxol | CR | |
PLCL1 | SNV | Missense_Mutation | c.3095N>T | p.Thr1032Ile | p.T1032I | Q15111 | protein_coding | deleterious(0.03) | benign(0.41) | TCGA-49-AAR2-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | taxol | CR | |
PLCL1 | SNV | Missense_Mutation | novel | c.241N>T | p.Asp81Tyr | p.D81Y | Q15111 | protein_coding | deleterious(0.01) | probably_damaging(0.981) | TCGA-50-5066-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |
PLCL1 | SNV | Missense_Mutation | c.260N>A | p.Cys87Tyr | p.C87Y | Q15111 | protein_coding | tolerated(0.05) | benign(0.188) | TCGA-50-5068-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | taxol | PD | |
PLCL1 | SNV | Missense_Mutation | c.2216N>A | p.Ala739Asp | p.A739D | Q15111 | protein_coding | deleterious(0) | possibly_damaging(0.777) | TCGA-50-5930-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxotere | PD | |
PLCL1 | SNV | Missense_Mutation | novel | c.1070T>G | p.Ile357Arg | p.I357R | Q15111 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-53-A4EZ-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
PLCL1 | SNV | Missense_Mutation | novel | c.2069N>C | p.Gly690Ala | p.G690A | Q15111 | protein_coding | tolerated(0.3) | benign(0.268) | TCGA-55-6968-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |